## **RETRACTION NOTE**

**Open Access** 



# Retraction Note: miR-3928v is induced by HBx via NF-kB/EGR1 and contributes to hepatocellular carcinoma malignancy by down-regulating VDAC3

Qiaoge Zhang<sup>1†</sup>, Ge Song<sup>1†</sup>, Lili Yao<sup>1</sup>, Yankun Liu<sup>1,2</sup>, Min Liu<sup>1</sup>, Shengping Li<sup>3</sup> and Hua Tang<sup>1\*†</sup>

### Retraction Note: J Exp Clin Cancer Res 37, 14 (2018) https://doi.org/10.1186/s13046-018-0681-y

The Editor in Chief has retracted this article. After publication, concerns were raised about Figs. 4d, 5e, and 6h. These were addressed in a Correction [1]. Later, a new concern arose around the similarity between two GADPH blots in Fig. 2f. The authors provided raw images, which raised further concerns regarding MMP2 blots. Additionally, concerns have been raised regarding the ethics approval documentation provided by the authors. The Editor in Chief, therefore, has lost confidence in the findings of the paper. All authors agree to this retraction.

#### **Author details**

<sup>1</sup>Tianjin Life Science Research Center and Department of Pathogen Biology, Collaborative Innovation Center of Tianjin for Medical Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, No. 22 Qi-Xiang-Tai Road, Tianjin 300070, China. <sup>2</sup>The Cancer Institute, Tangshan People's Hospital, Tangshan 063001, China. <sup>3</sup>Department of Hepatobiliary Oncology, State Key Laboratory of Oncology in Southern China, Cancer Center, Sun Yat-sen University, Guangzhou 510060, China.

The original article can be found online at https://doi.org/10.1186/s13046-018-0681-y  $\,$ 

<sup>†</sup>Qiaoge Zhang, Ge Song and Hua Tang contributed equally to this work.\*Correspondence: htang2002@yahoo.com; tangh@tmu.edu.cn

Full list of author information is available at the end of the article

Published online: 28 December 2022

#### Reference

1. Zhang Q, Song G, Yao L, et al. Correction to: miR-3928v is induced by HBx via NF-kB/EGR1 and contributes to hepatocellular carcinoma malignancy by down-regulating VDAC3. J Exp Clin Cancer Res. 2020;39:165. https://doi.org/10.1186/s13046-020-01655-2.



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/oublicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

<sup>&</sup>lt;sup>1</sup> Tianjin Life Science Research Center and Department of Pathogen Biology, Collaborative Innovation Center of Tianjin for Medical Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, No. 22 Qi-Xiang-Tai Road, Tianjin 300070, China